Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026

Moving Away from Asthma and COPD, Novartis Hones in on 20 Approvals by 2026

Source: 
BioSpace
News Tags: 
snippet: 

Two months after Novartis announced changes to streamline its operations, all systems appear to be running smoothly as the Swiss pharma giant turned in another strong quarter fueled by double digit growth in key, branded products.